Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) management will conduct a conference call for 10th August 2020 at 8:00 AM Eastern Time to discuss financial results and companys performance for 2Q20.
The conference call will also be available live on the website www.biohavenpharma.com
Earnings Expectation
Biohaven Pharmaceutical Holding Company Ltd. is reporting second quarter financial results on Monday 10th August 2020, before market open.
According to analysts surveyed by Thomson Reuters, BHVN is expected to report 2Q20 loss of $ 2.61 per share from revenue of $ 7.65 million. For the full year, analysts anticipate top line of $ 52.52 million, while looking forward to loss of $ 10.19 per share bottom line.
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders, Alzheimer diseases, and generalized anxiety disorders; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in is in phase III trial for neuro-inflammation.
